Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: Pooled analysis from the SPIRIT II, III, IV and COMPARE trials

EuroIntervention

Volumn 7, Issue 1, 2011, Pages 74-83

  Kereiakes, Dean J ^a   Smits, Pieter C ^b   Kedhi, Elvin ^b   Parise, Helen ^c   Fahy, Martin ^c   Serruys, Patrick W ^d   Stone, Gregg W ^c  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Maasstad Ziekenhuis ^*  (Netherlands)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical outcomes; Coronary artery disease; Drug eluting stents; Multivessel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; TICLOPIDINE; DRUG DERIVATIVE; RAPAMYCIN;

ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DATA BASE; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; DEATH; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS;

EID: 80051733441     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I1A14     Document Type: Article

References (31)

1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Hariai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies. Circulation 2009;119:3198-3206.
2. Serruys PW, Kutryk MJ, Ong AT. Coronary-Artery Stents. N Engl J Med 2006;354:483-495. (Pubitemid 43200299)
3. Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stîhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med 2009;360:961-972.
4. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-1674.
5. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-209.
6. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miguel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention 2006;2:286-294.
7. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the treatment of patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation2009;119:680-686.
8. Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009;158:520-526.e2.
9. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106. (Pubitemid 12205725)
10. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82: 1193-1202.
11. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk Features. Circulation2004;109:2290-2295. (Pubitemid 38678519)
12. Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, Shaw RE, Roe MT, Ho KK, Klein LW, Krone RJ, Weintraub WS, Brindis RG, Rumsfeld JS, Spertus JA; NCDR Registry Participants. Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention. J Am Coll Cardiol. 2010;55:1923-1932.
13. Dangas G, Moses JW. Is surgery preferred for the diabetic with multivessel disease? Debate on revascularization strategy for diabetic patients with multivessel coronary artery disease. Circulation. 2005;112:1507-1513. (Pubitemid 41291777)
14. Garg S, Stone GW, Kappetain AP, Sabik JF 3rd, Simonton C, Serruys PW. Clinical and angiographic risk assessment in patients with left main stem lesions. J Am Coll Cardiol Intv 2010;3:891-901.
15. Serruys PW, Satler L. Boyce SW, Mohr FW, Feldman TE, Kappetein AP, Colombo A, Mack MJ, Morice M-C, Stahle E, Leadley K, Dawkins KD, Holmes DR. Three-year follow-up of the SYNTAX trial: Optimal revascularization strategy in patients with left main disease. J Am Coll Cardiol 2010;56:B25 (abstract TCT-105).
16. Claessen BE, Stone GW, Smits PC, Kedhi E, Kikkert WJ, Piek JJ, Henriques JP. Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?; A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system. Neth Heart J. 2010;18:451-453.
17. Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multi-Vessel Stenting: Pooled Analysis from the SPIRIT III and SPIRIT IV Randomized Trials. J Am Coll Cardiol Intv 2010;3:1229-1239.
18. Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, Stone GW. Percutaneous revascularization in multivessel coronary disease is improved with everolimus-eluting stent deployment: Pooled analysis from the SPIRIT II, III, IV, and COMPARE trials. J Am Coll Cardiol 2011;57:E1643.
19. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial. J Am Med Assn 2008;299:1903-1913. (Pubitemid 351574920)
20. Stettler C, Wandel S, Allemann, S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948. (Pubitemid 47393576)
21. Song YB, Hahn JY, Choi SH, Choi JH, Lee SH, Jeong MH, Kim HS, Seong IW, Yang JY, Rha SW, Jang Y, Yoon JH, Tahk SJ, Seung KB, Park SJ, Gwon HC. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. J Am Coll Cardiol 2010;55:1743-1750.
22. Porto I, Selvanayagam JB, Van Gaal WJ, Prati F, Cheng A, Channon K, Neubauer S, Banning AP. Plaque Volume and Occurrence and Location of Periprocedural Myocardial Necrosis after Percutaneous Coronary Intervention. Circulation 2006;114:662-669.
23. Kereiakes DJ, Wang HP, Popma JJ, Kuntz RE, Donohoe DJ, Schofer J, Schampaert E, Meier B, Leon MB, Moses JW. Periprocedural and late consequences of Cypher stent overlap: pooled analysis of 5 clinical trials. J Am Coll Cardiol 2006;48:21-31. (Pubitemid 43929220)
24. Colombo A, Cosgrave, J. Paclitaxel-eluting stents in complex lesions. J Am Med Assn 2005;294:1268-1270. (Pubitemid 41352116)
25. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-278. (Pubitemid 40982311)
26. Popma JJ. Angiographic analysis of stent overlap / multiple stents from TAXUS V; Annual American College of Cardiology Scientific Session. Late Breaking Trials Orlando, FL, March 6, 2005.
27. Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Yamaguchi H, Tanouchi J, Yamada Y. High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent. Am Heart J. 2010;159:905-910.
28. Takano M, Yamamoto M, Murakami D, Inami S, Okamatsu K, Seimiya K, Ohba T, Seino Y, Mizuno K. Lack of association between large angiographic late loss and low risk of in-stent thrombus: angioscopic comparison between paclitaxel- and sirolimus-eluting stents. Circ Cardiovasc Interv. 2008;1:20-27.
29. Shinke T, Li J, Chen JP, Pendyala L, Goodchild T, Jabara R, Geva S, Ueno T, Chronos N, Robinson K, Hou D. High incidence of intramural thrombus after overlapping paclitaxel-eluting stent implantation: angioscopic and histopathologic analysis in porcine coronary arteries. Circ Cardiovasc Interv. 2008;1:28-35.
30. Stone GW, Rizvi A, Newman W, et al. for the SPIRIT IV investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two year follow-up from the SPIRIT IV trial. J Am Coll Cardiol (in press).
31. Smits PC. COMPARE: Two-year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. http://www.tctmd.com/txshow.aspx?tid= 1016260&id=102030&trid=1016256. Accessed November 28th, 2010.